| Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines (NCT05146999) | Galderma R&D | 2022-05-09 |
| Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines (NCT05321979) | Medytox Korea | 2022-02-07 |
| Study Comparing Treatment With Alluzience vs Reconstituted Toxin (NCT05277337) | Galderma R&D | 2022-02-04 |
| A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines (NCT05217355) | Medytox Korea | 2021-12-28 |
| Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD (NCT05129319) | Clinical Testing of Beverly Hills | 2021-12-16 |
| Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines (NCT05083286) | Clinical Testing of Beverly Hills | 2021-10-20 |
| Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines (NCT05059587) | Medytox Korea | 2021-08-30 |
| Split-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventional Palpation Technique (NCT05517538) | Mohamed Hayder Oleish Salih | 2021-08-09 |
| Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines (NCT04715048) | University of Southern California | 2021-01-01 |
| The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines (NCT04996810) | Protox Inc. | 2020-12-10 |
| Treatment of Moderate to Severe Glabellar Lines (NCT04249583) | Galderma R&D | 2020-02-10 |
| A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines (NCT04281095) | ATGC Co., Ltd. | 2019-11-01 |
| Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX® (NCT04281745) | Medy-Tox | 2019-10-17 |
| Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines (NCT03960957) | Galderma R&D | 2019-06-17 |
| Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines (NCT04143815) | Medy-Tox | 2019-05-20 |
| Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII) (NCT03985982) | Croma-Pharma GmbH | 2019-04-29 |
| The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines (NCT03837561) | Medy-Tox | 2018-12-13 |
| Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines (NCT03736928) | Galderma R&D | 2018-11-26 |
| Subject Satisfaction With AbobutulinumtoxinA Treatment (NCT03687736) | Galderma R&D | 2018-10-02 |
| The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines (NCT03440671) | Huons Co., Ltd. | 2017-11-30 |
| Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines (NCT03289169) | Medy-Tox | 2016-12-30 |
| Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (NCT03004248) | Revance Therapeutics, Inc. | 2016-12-09 |
| Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (NCT03014622) | Revance Therapeutics, Inc. | 2016-12-08 |
| Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (NCT03014635) | Revance Therapeutics, Inc. | 2016-12-05 |
| Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II (NCT02677805) | Croma-Pharma GmbH | 2016-03-30 |
| Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I (NCT02677298) | Croma-Pharma GmbH | 2016-03-02 |
| Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006 (NCT02428608) | Evolus, Inc. | 2015-05-01 |
| A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001 (NCT02334423) | Evolus, Inc. | 2015-01-01 |
| A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002 (NCT02334436) | Evolus, Inc. | 2015-01-01 |
| Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines (NCT02236312) | Galderma R&D | 2014-09-01 |
| A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines (NCT02108158) | Galderma R&D | 2014-04-01 |
| The Treatment of Glabellar Frown Lines (NCT02096081) | Merz North America, Inc. | 2014-02-01 |
| Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line (NCT03908008) | Medy-Tox | 2014-01-01 |
| A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device (NCT01801826) | Pacira Pharmaceuticals, Inc | 2013-01-01 |
| Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device (NCT01808742) | Pacira Pharmaceuticals, Inc | 2012-11-01 |
| Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines (NCT01485601) | Medy-Tox | 2011-12-07 |
| Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines (NCT01391312) | Allergan | 2011-06-01 |
| NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines (NCT00777803) | Merz Pharmaceuticals GmbH | 2008-11-01 |
| Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines (NCT00430586) | Merz Pharmaceuticals GmbH | 2006-11-01 |